Summarized by Masters of Longevity from PR Newswire.
A business news article about a licensing deal for a once-weekly oral GLP-1/GIP drug, outlining the agreement’s strategic scope and commercial implications.
Key Takeaways
- Novo Nordisk obtained exclusive global rights outside Greater China and Taiwan to develop and commercialize HRS-1596.
- Hengrui Pharma will receive a $300 million upfront payment and up to $2.6 billion total contingent milestones.
- HRS-1596 is a once-weekly oral GLP-1/GIP dual agonist designed for weight management and type 2 diabetes and is phase I-ready in China.
